^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® EML4-ALK Fusion Gene Detection Kit

    Company:
    Amoy Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    21h
    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (clinicaltrials.gov)
    P2, N=109, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    EML4 (EMAP Like 4)
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    VENTANA ALK (D5F3) CDx Assay • Vysis ALK Break Apart FISH Probe Kit • AmoyDx® EML4-ALK Fusion Gene Detection Kit
    |
    Lorbrena (lorlatinib)
    almost2years
    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (clinicaltrials.gov)
    P2; Trial completion date: Aug 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    EML4 (EMAP Like 4)
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    VENTANA ALK (D5F3) CDx Assay • Vysis ALK Break Apart FISH Probe Kit • AmoyDx® EML4-ALK Fusion Gene Detection Kit
    |
    Lorbrena (lorlatinib)
    almost2years
    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (clinicaltrials.gov)
    P2; Trial completion date: Aug 2022 --> Aug 2023
    Trial completion date
    |
    EML4 (EMAP Like 4)
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    VENTANA ALK (D5F3) CDx Assay • Vysis ALK Break Apart FISH Probe Kit • AmoyDx® EML4-ALK Fusion Gene Detection Kit
    |
    Lorbrena (lorlatinib)
    over2years
    Alercell® to distribute Amoy Diagnostics’ molecular cancer tests (Alercell Press Release)
    "Alercell® announced today that it has entered into a master distribution agreement with Amoy Diagnostics Co., Ltd (AmoyDx)...The master distribution agreement enables Alercell® to introduce to the United States market several innovative DNA sequencing cancer tests...The first tests to be introduced under the Agreement include: Pan Lung Cancer PCR Panel, EML4-ALK Fusion Gene Detection Kit, BRCA Pro Panel, and the Human Papillomavirus (HPV) Genotyping Detection Kit. These molecular diagnostic tests are all introduced as RUOs (Research Use Only) and are the most advanced next generation DNA sequencing tests in various fields to tackle, Lung Cancer, Breast Cancer , Ovarian Cancer and Cervical Cancer screening."
    Licensing / partnership
    |
    AmoyDx® Pan Lung Cancer PCR Panel • AmoyDx® BRCA Pro Panel • AmoyDx® EML4-ALK Fusion Gene Detection Kit • AmoyDx® Human Papillomavirus (HPV) Genotyping Detection Kit